Nonalcoholic Steatohepatitis (NASH) is a progressive liver disease marked by inflammation, liver cell damage, and fibrosis. As an advanced form of Non-Alcoholic Fatty Liver Disease (NAFLD), it affects millions globally. Despite the rising prevalence of NASH, there are currently no FDA-approved therapies for NASH, making it a key focus for ongoing